September 04, 2014 17:30 ET
MONTREAL, QUEBEC--(Marketwired - Sept. 4, 2014) -
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Pediapharm Inc. ("Pediapharm" or the "Company") (TSX VENTURE:PDP) announces that its Board of Directors has approved the grant of 180,000 stock options to a director of the Company who was appointed on June 2, 2014, subject to regulatory and TSX Venture Exchange approval. The options were issued with an exercise price of $0.30 per share and have a term of ten (10) years. The options vest the following way: 1/3 immediately, 1/3 on September 4, 2015 and 1/3 on September 4, 2016.
About Pediapharm Inc.
Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; KoolEffect™ which reduces the symptoms of fever; and VapoLyptus™; a soothing vapour patch of Eucalyptus and Camphor.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sylvain Chretien, Presidentand Chief Executive OfficerPediapharm Inc.514-762-2626 ext. email@example.comRoland Boivin, Chief Financial OfficerPediapharm Inc.514-762-2626 ext. firstname.lastname@example.orgRelations Publiques Paradox Public Relations Inc.Carl Desjardins514email@example.com
See all RSS Newsfeeds